KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EBT: 2009-2024

Historic EBT for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to $248.5 million.

  • Vertex Pharmaceuticals' EBT rose 6.10% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year increase of 1613.67%. This contributed to the annual value of $248.5 million for FY2024, which is 94.33% down from last year.
  • As of FY2024, Vertex Pharmaceuticals' EBT stood at $248.5 million, which was down 94.33% from $4.4 billion recorded in FY2023.
  • In the past 5 years, Vertex Pharmaceuticals' EBT registered a high of $4.4 billion during FY2023, and its lowest value of $248.5 million during FY2024.
  • For the 3-year period, Vertex Pharmaceuticals' EBT averaged around $3.0 billion, with its median value being $4.2 billion (2022).
  • Its EBT has fluctuated over the past 5 years, first soared by 123.45% in 2020, then tumbled by 94.33% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' EBT (Yearly) stood at $3.1 billion in 2020, then fell by 12.40% to $2.7 billion in 2021, then skyrocketed by 55.01% to $4.2 billion in 2022, then climbed by 3.48% to $4.4 billion in 2023, then crashed by 94.33% to $248.5 million in 2024.